文献速递类风湿关节炎

修订版布里斯托尔类风湿关节炎疲劳评估工具与类风湿关节炎疾病影响量表:六国验证

The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

在法国、德国、荷兰、西班牙、瑞典和英国对1276例类风湿关节炎患者进行调查,评估BRAF-MDQ、修订版BRAF-NRS V2及RAID量表的因子结构、内部一致性和结构效度。结果显示BRAF-MDQ四因子结构和RAID单因子结构在各国均得到确认,内部一致性良好,修订版BRAF-NRS V2应对条目效度优于原版并替代原版。

要点

  • BRAF-MDQ四因子结构和RAID单因子结构在六个国家均得到确认,各因子解释条目变异≥66%。
  • BRAF-MDQ总量表及子量表Cronbach's α为0.75-0.96,RAID为0.93-0.96。
  • 修订版BRAF-NRS V2应对条目在所有分析中效度均优于原版,替代原版。

核心结论

  • 在六个欧洲国家中,BRAF-MDQ识别出相同的四个方面疲劳,与RAID均显示出强因子结构、内部一致性和中等至良好的结构效度。
  • 修订版BRAF-NRS V2显示出改善的结构效度,并替代原版。

研究设计与样本

  • 调查了法国、德国、荷兰、西班牙、瑞典和英国的类风湿关节炎患者,共1276例参与(76%女性,25%病程<5年,中位HAQ 1.0)。
  • 调查内容包括HAQ、36项简短健康调查(SF-36)以及BRAF-NRS应对条目和西班牙RAID应对条目的潜在修订版。
  • 通过因子分析和Cronbach's α检验因子结构与内部一致性,通过Spearman相关检验结构效度。

主要发现

  • 原始BRAF-MDQ四因子结构和RAID单因子结构在每个国家均得到确认,每个因子解释条目变异的⩾66%,所有条目因子负荷为0.71-0.98。
  • BRAF-MDQ总量表及子量表的内部一致性Cronbach's α为0.75-0.96,RAID为0.93-0.96。
  • BRAF-MDQ及BRAF-NRS严重程度和影响量表显示疲劳结构效度,与SF-36活力维度和RAID疲劳内部相关(r=0.63-0.93)。
  • BRAFs和RAID的更广泛结构效度通过彼此之间、与HAQ和SF-36各域的相关显示(r=0.46-0.82),各国模式相似。
  • 修订版BRAF-NRS V2应对条目在所有分析中效度均强于原版;修订版西班牙RAID应对条目表现与原版相当。

关键数值与推荐

  • BRAF-MDQ四因子结构解释条目变异⩾66%,条目因子负荷0.71-0.98。
  • BRAF-MDQ总量表及子量表Cronbach's α为0.75-0.96,RAID为0.93-0.96。
  • 疲劳结构效度:与SF-36活力维度和RAID疲劳相关r=0.63-0.93。
  • 更广泛结构效度:BRAFs与RAID彼此之间、与HAQ和SF-36各域相关r=0.46-0.82。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ), the revised Bristol Rheumatoid Arthritis Numerical Rating Scales (BRAF-NRS V2) and the Rheumatoid Arthritis Impact of Disease (RAID) scale in six countries. METHODS: We surveyed RA patients in France, Germany, The Netherlands, Spain, Sweden and the UK, including the HAQ, 36-item Short Form Health Survey (SF-36) and potential revisions of the BRAF-NRS coping and Spanish RAID coping items. Factor structure and internal consistency were examined by factor analysis and Cronbach's α and construct validity by Spearman's correlation. RESULTS: A total of 1276 patients participated (76% female, 25% with a disease duration <5 years, median HAQ 1.0). The original BRAF-MDQ four-factor structure and RAID single-factor structure were confirmed in every country with ⩾66% of variation in items explained by each factor and all item factor loadings of 0.71-0.98. Internal consistency for the BRAF-MDQ total and subscales was a Cronbach's α of 0.75-0.96 and for RAID, 0.93-0.96. Fatigue construct validity was shown for the BRAF-MDQ and BRAF-NRS severity and effect scales, correlated internally with SF-36 vitality and with RAID fatigue (r = 0.63-0.93). Broader construct validity for the BRAFs and RAID was shown by correlation with each other, HAQ and SF-36 domains (r = 0.46-0.82), with similar patterns in individual countries. The revised BRAF-NRS V2 Coping item had stronger validity than the original in all analyses. The revised Spanish RAID coping item performed as well as the original. CONCLUSION: Across six European countries, the BRAF-MDQ identifies the same four aspects of fatigue, and along with the RAID, shows strong factor structure and internal consistency and moderate-good construct validity. The revised BRAF-NRS V2 shows improved construct validity and replaces the original.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hewlett S, Kirwan J, Bode C, et al. The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology (Oxford). 2018. PMID: 29087507. doi:10.1093/rheumatology/kex370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。